Checkpoint Capital L.P. Rhythm Pharmaceuticals, Inc. Transaction History
Checkpoint Capital L.P.
- $202 Billion
- Q3 2024
A detailed history of Checkpoint Capital L.P. transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Checkpoint Capital L.P. holds 663,381 shares of RYTM stock, worth $39.3 Million. This represents 17.24% of its overall portfolio holdings.
Number of Shares
663,381
Previous 922,100
28.06%
Holding current value
$39.3 Million
Previous $37.9 Billion
8.21%
% of portfolio
17.24%
Previous 22.82%
Shares
4 transactions
Others Institutions Holding RYTM
# of Institutions
193Shares Held
67.1MCall Options Held
834KPut Options Held
78.6K-
Primecap Management CO Pasadena, CA7.22MShares$427 Million0.28% of portfolio
-
Black Rock Inc. New York, NY6.74MShares$399 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.4MShares$379 Million3.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$360 Million4.44% of portfolio
-
Goldman Sachs Group Inc New York, NY3.88MShares$230 Million0.03% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $3.3B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...